

Supplementary Table S1: LPV pediatric dosing guidelines

			WHO guidelines 2010						CHAPAS-2 Protocol								
			Liquid (80/20 mg/mL)			Pediatric tablet (100/25mg)			Innovator syrup (80/20 mg/mL)			Minitab sprinkle (40/10 mg)			Generic pediatric tablet (100/25 mg)		
			LPV daily dose*			LPV daily dose*			LPV daily dose			LPV daily dose			LPV daily dose		
body weight (kg)	body surface area (m ²)*		mg	mg/m ²		mg	mg/m ²		mg	mg/m ²		mg	mg/m ²		mg	mg/m ²	
	min	max		min	max		min	max		min	max		min	max		min	max
5-<7	0.3	0.38	240	632	800	-	-	-	240	632	800	240	632	800	-	-	-
7-<10	0.38	0.49	240	490	632	-	-	-	240	490	632	240	490	632	-	-	-
10-<12	0.49	0.56	320	571	653	300	536	612	320	571	653	320	571	653	300	536	612
12-<14	0.56	0.62	320	516	571	300	484	536	320	516	571	320	516	571	300	484	536
14-<20	0.62	0.79	400	506	645	400	506	645	400	506	645	400	506	645	400	506	645
20-<25	0.79	0.92	480	522	608	400	435	506	480	522	608	480	522	608	500	543	633
25-<30	0.92	1.1	560	509	609	600	545	652	560	509	609	560	509	609	600	545	652
30-<35	1.1	1.2	640	533	582	600	500	545	560	467	509	560	467	509	600	500	545

* Based on standard from pediatric oncology¹¹.

† Target daily LPV dosage of WHO 2010 is 230-350 mg/m² twice-daily (=460-700 mg/m² LPV daily dose)

Note: bold indicates where CHAPAS-2 protocol dosing differed from WHO 2010.

- 5 Note: bold indicates where CHAPAS-2 protocol dosing differed from WHO 2010. Footnote: No child in any cohort reported any problems knowing which bottle contained which drug on any formulation. No problems losing/breaking bottles were reported in either minitab sprinkle/syrup cohort (3-<12m or 1-<4y) on any formulation. No problems with weight of the bottles, opening the bottles, the number or conspicuousness of the bottles or with losing/breaking capsules were reported on either formulation in the 1-4y minitab sprinkle/syrup cohort or the 4->13y minitab sprinkle/tablet cohort. No problems transporting bottles or vomiting medicine
- 10 were reported on either formulation in the 4-<13y minitab sprinkle/tablet cohort.

Supplementary Figure S1

